Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)

NCT03578198 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT03578198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03578198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Rituximab Plus MG4101 in Patients With Relapsed or Refractory Indolent CD20-positive Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
November 8, 2018
Completion date
April 7, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd20-positive non-hodgkin lymphoma